BioLineRx (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing therapeutic candidates, according to the company’s website (see here: www.biolinerx.com). SNNLive spoke with Philip Serlin, CPA, MBA, CEO of BioLineRx Ltd. at the LD Micro "Main Event" 2016 in Bel Air, CA.
In this video interview, Mr. Serlin and our host discuss the following topics:
- Overview of BioLineRx
- Discusses why focus in Israel
- Business model
- History of the company
- Criteria the company looks for when evaluating a company to bring into their portfolio
- Mr. Serlin’s background
For more information about BioLineRx, please visit: www.biolinerx.com
The interview may contain forward-looking statements about BioLineRx Ltd. See BioLineRx's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions